Latest Pharma Insights
Agios Secures Oscotec’s Next Generation SYK Inhibitor In $665m Deal
Deal expands Agios's rare hematology portfolio in high-need area and marks another major global alliance involving Oscotec, validating the Korean industry's rising competitiveness in innovative drug development.
Scrip - June 2, 2026
Deal expands Agios's rare hematology portfolio in high-need area and marks another major global alliance involving Oscotec, validating the Korean industry's rising competitiveness in innovative drug development.
Scrip - June 2, 2026
ASCO: CStone’s First-In-Class Trispecific Shows Strong Activity In 1L NSCLC
Strong efficacy signs for Alphamab’s anti-HER2 bispecific in the neoadjuvant setting lay a firm foundation for its use in early breast cancer, while early data for CStone’s first-in-class trispecific offer a strong basis for a planned global Phase III trial in lung cancer.
Scrip - June 2, 2026
Strong efficacy signs for Alphamab’s anti-HER2 bispecific in the neoadjuvant setting lay a firm foundation for its use in early breast cancer, while early data for CStone’s first-in-class trispecific offer a strong basis for a planned global Phase III trial in lung cancer.
Scrip - June 2, 2026
Agios Secures Oscotec’s Next Generation SYK Inhibitor In $665m Deal
Deal expands Agios's rare hematology portfolio in high-need area and marks another major global alliance involving Oscotec, validating the Korean industry's rising competitiveness in innovative drug development.
Scrip - June 2, 2026
Deal expands Agios's rare hematology portfolio in high-need area and marks another major global alliance involving Oscotec, validating the Korean industry's rising competitiveness in innovative drug development.
Scrip - June 2, 2026
ASCO: CStone’s First-In-Class Trispecific Shows Strong Activity In 1L NSCLC
Strong efficacy signs for Alphamab’s anti-HER2 bispecific in the neoadjuvant setting lay a firm foundation for its use in early breast cancer, while early data for CStone’s first-in-class trispecific offer a strong basis for a planned global Phase III trial in lung cancer.
Scrip - June 2, 2026
Strong efficacy signs for Alphamab’s anti-HER2 bispecific in the neoadjuvant setting lay a firm foundation for its use in early breast cancer, while early data for CStone’s first-in-class trispecific offer a strong basis for a planned global Phase III trial in lung cancer.
Scrip - June 2, 2026
Child Death Overseas Prompts KayserBetten To Replace Hand Controls On Pediatric Care Beds In US
KayserBetten is recalling pediatric care beds marketed in the US due to a potential hazard from the lock on the hand controls. If not properly locked, there’s an increased risk of a child becoming trapped under the bed frame.
Medtech Insight - June 1, 2026
KayserBetten is recalling pediatric care beds marketed in the US due to a potential hazard from the lock on the hand controls. If not properly locked, there’s an increased risk of a child becoming trapped under the bed frame.
Medtech Insight - June 1, 2026
Global Medtech Guidance Tracker: May 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 60 documents have been posted on the tracker since its last update.
Medtech Insight - June 1, 2026
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 60 documents have been posted on the tracker since its last update.
Medtech Insight - June 1, 2026
A Technology Problem Disguised As A Trust Problem: J&J’s Polyphonic President On Scaling Surgical AI
Medicine says "do no harm." Software says "move fast and break things." J&J's Shan Jegatheeswaran on reconciling the two as healthcare moves into software — starting with the Abu Dhabi collaboration.
Medtech Insight - June 1, 2026
Medicine says "do no harm." Software says "move fast and break things." J&J's Shan Jegatheeswaran on reconciling the two as healthcare moves into software — starting with the Abu Dhabi collaboration.
Medtech Insight - June 1, 2026
Ten-Year Data Show Edwards’ RESILIA Tissue Valves Hold Up Even In Younger Patients
Ten years of data from the COMMENCE trial show Edwards Lifesciences' RESILIA tissue valves holding firm where biological valves have historically faltered – in younger patients who need durability measured in decades, not just years.
Medtech Insight - June 1, 2026
Ten years of data from the COMMENCE trial show Edwards Lifesciences' RESILIA tissue valves holding firm where biological valves have historically faltered – in younger patients who need durability measured in decades, not just years.
Medtech Insight - June 1, 2026
Is European ‘Reliability’ Enough In The Moving Picture Of Global Markets?
MedTech Europe directors Diana Kanecka and Jesús Rueda sat down with Medtech Insight at the MedTech Forum 2026 to survey the global medtech landscape and discuss whether it remains one of opportunity for European manufacturers and exporters.
Medtech Insight - June 1, 2026
MedTech Europe directors Diana Kanecka and Jesús Rueda sat down with Medtech Insight at the MedTech Forum 2026 to survey the global medtech landscape and discuss whether it remains one of opportunity for European manufacturers and exporters.
Medtech Insight - June 1, 2026
DSM-Firmenich Helps Prep Brands for BEMT US Launch – Senior Manager
Dutch company DSM-Firmenich is helping its brand partners with ‘launch readiness’ for their skin care containing BEMT, also known as PARSOL Shield.
HBW Insight - June 1, 2026
Dutch company DSM-Firmenich is helping its brand partners with ‘launch readiness’ for their skin care containing BEMT, also known as PARSOL Shield.
HBW Insight - June 1, 2026
Galderma’s Launch Of Differin Epiduo OTC Switch, Unlike Differin, Won’t Have Exclusivity
Adapalene/benzoyl peroxide acne gel isn’t receiving three-year market exclusivity as part of FDA’s recent approval of Galderma Labs’ NDA. Galderma expects to launch Differin Epiduo during summer this year “with broad availability across both in-store and online channels.”
HBW Insight - June 1, 2026
Adapalene/benzoyl peroxide acne gel isn’t receiving three-year market exclusivity as part of FDA’s recent approval of Galderma Labs’ NDA. Galderma expects to launch Differin Epiduo during summer this year “with broad availability across both in-store and online channels.”
HBW Insight - June 1, 2026
Cooper Acquires Spain’s ‘Number-One Analgesic’ As Ferrer Exits OTC
As Ferrer quits OTC to focus on pharma, Cooper Consumer Health gains leading Spanish analgesic brand Gelocatil to further enhance its own growing portfolio in the country.
HBW Insight - June 1, 2026
As Ferrer quits OTC to focus on pharma, Cooper Consumer Health gains leading Spanish analgesic brand Gelocatil to further enhance its own growing portfolio in the country.
HBW Insight - June 1, 2026
Samsung Bioepis Joins EU Eylea Rivals
Samsung Bioepis has become the latest competitor to launch a biosimilar aflibercept rival to Eylea in Europe. The Korean firm will market is Opuviz version through its own network, alongside its Byooviz ranibizumab rival to Lucentis.
Generics Bulletin - June 1, 2026
Samsung Bioepis has become the latest competitor to launch a biosimilar aflibercept rival to Eylea in Europe. The Korean firm will market is Opuviz version through its own network, alongside its Byooviz ranibizumab rival to Lucentis.
Generics Bulletin - June 1, 2026
Teva’s TAPI Sale Hits Succession Question
The departure of TAPI’s chief executive officer, set for July 3, raises fresh questions over the timing of Teva’s long-running effort to divest its active pharmaceutical ingredients arm.
Generics Bulletin - June 1, 2026
The departure of TAPI’s chief executive officer, set for July 3, raises fresh questions over the timing of Teva’s long-running effort to divest its active pharmaceutical ingredients arm.
Generics Bulletin - June 1, 2026
China Approval Seals Henlius’ Global Breast Cancer Play
Chinese approval for Hanbeiyou completes Henlius’ China-US-EU pertuzumab sweep, strengthening its dual-target HER2 breast cancer strategy and expanding its global biosimilar ambitions.
Generics Bulletin - June 1, 2026
Chinese approval for Hanbeiyou completes Henlius’ China-US-EU pertuzumab sweep, strengthening its dual-target HER2 breast cancer strategy and expanding its global biosimilar ambitions.
Generics Bulletin - June 1, 2026
What’s Next? Five Things To Look Out For In June
Generics Bulletin previews the most noteworthy and anticipated events for June 2026.
Generics Bulletin - June 1, 2026
Generics Bulletin previews the most noteworthy and anticipated events for June 2026.
Generics Bulletin - June 1, 2026
EU Medtech CEOs Keen To Map Out The Fixes From Draghi Report
How to bring the competitive spark back to Europe was the underlying theme of a CEOs Unfiltered session at the MedTech Forum 2026, whose panelists said there is much EU decision makers can do.
In Vivo - June 1, 2026
How to bring the competitive spark back to Europe was the underlying theme of a CEOs Unfiltered session at the MedTech Forum 2026, whose panelists said there is much EU decision makers can do.
In Vivo - June 1, 2026
The Nighttime Evidence Gap: How Passive Monitoring Could Reshape Trial Endpoints
Clinical trials capture daytime physiology with growing precision — but most still miss what happens at night. Passive monitoring is changing that, revealing treatment effects, early warning signals and endpoint data that patient recall tools cannot provide.
In Vivo - June 1, 2026
Clinical trials capture daytime physiology with growing precision — but most still miss what happens at night. Passive monitoring is changing that, revealing treatment effects, early warning signals and endpoint data that patient recall tools cannot provide.
In Vivo - June 1, 2026